Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan P Venook

Showing results (91-100 of 246) with videos related to

Pageof 25
Sort By:
Clinical Colorectal Cancer|January 16, 2013
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405Katherine Van Loon, Devin Wigler, Donna Niedzwiecki, et al.
Clinical Colorectal Cancer|December 17, 2005
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinomaAlan P Venook, Charles D Blanke, Donna Niedzwiecki, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 14, 2008
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinomaRichard K Sterling, Lennox Jeffers, Fredric Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of MutationsFederico Innocenti, Wancen Mu, Xueping Qu, et al.
Journal of Gastrointestinal Oncology|March 14, 2022
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatinGreg Yothers, Alan P Venook, Eiji Oki, et al.
Investigational New Drugs|April 2, 2008
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Andrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Journal of the National Cancer Institute|August 8, 2014
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)Katherine Van Loon, Kouros Owzar, Chen Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Andrew B Nixon, Herbert Pang, Mark D Starr, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerAndrew H Ko, Alan P Venook, Emily K Bergsland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2014
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Stephanie M Cushman, Chen Jiang, Ace J Hatch, et al.
Pageof 25

Showing results (91-100 of 246) with videos related to

Sort By:
Pageof 25
Clinical Colorectal Cancer|January 16, 2013
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405Katherine Van Loon, Devin Wigler, Donna Niedzwiecki, et al.
Clinical Colorectal Cancer|December 17, 2005
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinomaAlan P Venook, Charles D Blanke, Donna Niedzwiecki, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 14, 2008
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinomaRichard K Sterling, Lennox Jeffers, Fredric Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of MutationsFederico Innocenti, Wancen Mu, Xueping Qu, et al.
Journal of Gastrointestinal Oncology|March 14, 2022
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatinGreg Yothers, Alan P Venook, Eiji Oki, et al.
Investigational New Drugs|April 2, 2008
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Andrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Journal of the National Cancer Institute|August 8, 2014
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)Katherine Van Loon, Kouros Owzar, Chen Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Andrew B Nixon, Herbert Pang, Mark D Starr, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerAndrew H Ko, Alan P Venook, Emily K Bergsland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2014
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Stephanie M Cushman, Chen Jiang, Ace J Hatch, et al.
Pageof 25